-
1.发明授权N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer 有权N2，N4-双（4-（哌嗪-1-基）苯基）吡啶嘧啶-2,4-二胺衍生物或其药学上可接受的盐，以及含有作为预防或治疗癌症的活性成分的组合物公开(公告)号：US09199944B2
公开(公告)日：2015-12-01
申请号：US14617079
申请日：2015-02-09
Inventor： Kwangho Lee , Hyoung Rae Kim , Chi Hoon Park , Chong Ock Lee , Jong Kook Lee , Hee Jung Jung , Sung Yun Cho , Chong Hak Chae , Sang Un Choi , Jae Du Ha
IPC: A61K31/506 , C07D239/48 , C07D403/12 , C07D403/14
CPC classification number: C07D239/48 , A61K31/506 , C07D403/12 , C07D403/14
Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
Abstract translation: 本文公开了一种新的N 2，N 4 - 双（4-（哌嗪-1-基）苯基）嘧啶-2,4-二胺衍生物或其药学上可接受的盐和用于预防或治疗含有其的癌症的药物组合物 作为活性成分。 本发明的化合物对于间变性淋巴瘤激酶（ALK）和活化的cdc42相关激酶（ACK1）的活性具有优异的抑制作用，因此可以改善对具有间变性淋巴瘤激酶融合蛋白的癌细胞的治疗效果，例如 EML4-ALK和NPM-ALK，并且还有效地预防癌症的复发因此可用作用于预防和治疗癌症的药物组合物。
-
公开(公告)号：US10053458B2
公开(公告)日：2018-08-21
申请号：US15319151
申请日：2015-05-21
Inventor： Chang Soo Yun , Hyoung Rae Kim , Sung Yun Cho , Hee Jung Jung , Kwangho Lee , Chong Hak Chae , Chong Ock Lee , Chi Hoon Park , Pilho Kim , Jong Yeon Hwang , Jae Du Ha , Sun Joo Ahn
IPC: C07D471/04 , C07D405/14 , C07D401/14 , C07D403/12 , C07D401/12
CPC classification number: C07D471/04 , A61K31/506 , C07D209/04 , C07D239/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14
Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
-
公开(公告)号：US09403831B2
公开(公告)日：2016-08-02
申请号：US14435974
申请日：2013-09-30
Inventor： Hee Jung Jung , Jae Du Ha , Sung Yun Cho , Hyoung Rae Kim , Kwang Ho Lee , Chong Ock Lee , Sang Un Choi , Chi Hoon Park
IPC: C07D487/04 , A61K31/4985
CPC classification number: C07D487/04 , A61K31/4985
Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
Abstract translation: 本发明涉及一种新型的三唑并吡嗪衍生物或其药学上可接受的盐，以及含有其作为预防或治疗高增殖性病症的活性成分的药物组合物。 通过有效抑制c-Met酪氨酸激酶活性，本发明可用作与由异常激酶活性如癌症，银屑病，类风湿性关节炎和糖尿病性视网膜病引起的过度细胞增殖和生长相关的各种高增殖性疾病的治疗剂 。
-
公开(公告)号：US10369149B2
公开(公告)日：2019-08-06
申请号：US15567224
申请日：2015-12-30
Inventor： Jong Yeon Hwang , Hyoung Rae Kim , Jae Du Ha , Sung Yun Cho , Hee Jung Jung , Pilho Kim , Chang Soo Yun , Chong Ock Lee , Chi Hoon Park , Chong Hak Chae , Sunjoo Ahn
IPC: A61K31/506 , C07D239/30 , C07D239/48 , A23L33/10 , A61P35/00 , C07B43/04 , C07C13/48
Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
-
公开(公告)号：US10100019B2
公开(公告)日：2018-10-16
申请号：US15565897
申请日：2016-04-06
Inventor： Pilho Kim , Hyoung Rae Kim , Sung Yun Cho , Jae Du Ha , Hee Jung Jung , Chang Soo Yun , Jong Yeon Hwang , Chi Hoon Park , Chong Ock Lee , Sunjoo Ahn , Chong Hak Chae
IPC: C07D239/48 , A61K31/505 , A61P35/00 , A23L33/10 , A23L33/00 , C07D401/12 , C07D403/12
Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
-
Patent Agency Ranking
公开(公告)号：US20220009933A1
公开(公告)日：2022-01-13
申请号：US17294705
申请日：2019-11-20
Inventor： Heeyeong Cho , Hee-Jong Lim , Woo Kyu Park , Dae Young Jeong , Hyeon Young Kim , Sae-Bom Yoon , Chong Ock Lee , Heung Kyoung Lee , Victor Sukbong HONG , Ji Hye Choi
IPC: C07D487/04 , C07D519/00 , C07D487/14 , A23L33/10
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient, wherein the tricyclic compound represented by Chemical Formula 1 has an excellent inhibitory activity against IRAK4, and thus can be usefully used for the prevention, treatment, or alleviation of autoimmune diseases or tumors.
-
公开(公告)号：US11192878B2
公开(公告)日：2021-12-07
申请号：US16609805
申请日：2018-05-11
Inventor： Jong Yeon Hwang , Jae Du Ha , Sung Yun Cho , Pil Ho Kim , Chang Soo Yun , Chi Hoon Park , Chong Ock Lee , Sang Un Choi , Joo Youn Lee , Sunjoo Ahn
IPC: C07D401/04 , A61P35/00 , C07D401/14
Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
-
公开(公告)号：US11084824B2
公开(公告)日：2021-08-10
申请号：US16612592
申请日：2018-05-14
Inventor： Pilho Kim , Sung Yun Cho , Jae Du Ha , Hyoung Rae Kim , Jong Yeon Hwang , Chang Soo Yun , Hee Jung Jung , Chi Hoon Park , Chong Ock Lee , Chang Hoon Lee , Sunjoo Ahn
IPC: A61K31/519 , A61P25/16 , A61P35/00 , A61P37/00 , C07D487/04 , A23L33/10
Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
-
公开(公告)号：US20180111905A1
公开(公告)日：2018-04-26
申请号：US15565897
申请日：2016-04-06
Inventor： Pilho Kim , Hyoung Rae Kim , Sung Yun Cho , Jae Du Ha , Hee Jung Jung , Chang Soo Yun , Jong Yeon Hwang , Chi Hoon Park , Chong Ock Lee , Sunjoo Ahn , Chong Hak Chae
IPC: C07D239/48 , A61P35/00 , C07D401/12 , C07D403/12 , A23L33/00 , A23L33/10
CPC classification number: C07D239/48 , A23L33/10 , A23L33/30 , A23L33/40 , A23V2002/00 , A61K31/505 , A61P35/00 , C07D401/12 , C07D403/12
Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
-
公开(公告)号：US20150259350A1
公开(公告)日：2015-09-17
申请号：US14435974
申请日：2013-09-30
Inventor： Hee Jung Jung , Jae Du Ha , Sung Yun Cho , Hyoung Rae Kim , Kwang Ho Lee , Chong Ock Lee , Sang Un Choi , Chi Hoon Park
IPC: C07D487/04
CPC classification number: C07D487/04 , A61K31/4985
Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
Abstract translation: 本发明涉及一种新型的三唑并吡嗪衍生物或其药学上可接受的盐，以及含有其作为预防或治疗高增殖性病症的活性成分的药物组合物。 通过有效抑制c-Met酪氨酸激酶活性，本发明可用作与由异常激酶活性如癌症，银屑病，类风湿性关节炎和糖尿病性视网膜病引起的过度细胞增殖和生长相关的各种高增殖性疾病的治疗剂 。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.024 seconds)
